Literature DB >> 26344419

Olaparib.

S C Goulooze1, A F Cohen1,2, R Rissmann1,2.   

Abstract

Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.
© 2015 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26344419      PMCID： PMC4693566          DOI： 10.1111/bcp.12761

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  6 in total

1.  PARP inhibitors in BRCA mutation-associated ovarian cancer.

Authors:  Andrew Clamp; Gordon Jayson
Journal:  Lancet Oncol       Date:  2014-12-04       Impact factor: 41.316

Review 2.  Error-Prone Repair of DNA Double-Strand Breaks.

Authors:  Kasey Rodgers; Mitch McVey
Journal:  J Cell Physiol       Date:  2016-01       Impact factor: 6.384

3.  Olaparib.

Authors:  S C Goulooze; A F Cohen; R Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-10-24       Impact factor: 4.335

4.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Authors:  Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

Review 5.  The role of PARP in DNA repair and its therapeutic exploitation.

Authors:  M Javle; N J Curtin
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

6.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2014-05-31       Impact factor: 41.316
  6 in total
  7 in total

1.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

2.  Olaparib.

Authors:  S C Goulooze; A F Cohen; R Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-10-24       Impact factor: 4.335

3.  Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.

Authors:  Yan Wu; Tianyu Wu; Xin Hu; Simeng Xu; Di Xiao; Jingtao Wu; Xinjian Yan; Xiaoping Yang; Gaofeng Li
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

Review 4.  New and Emerging Targeted Therapies for Advanced Breast Cancer.

Authors:  Kristie H Lau; Alexandra M Tan; Yihui Shi
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

5.  HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.

Authors:  Benigno C Valdez; Yago Nieto; Bin Yuan; David Murray; Borje S Andersson
Journal:  Oncotarget       Date:  2022-10-14

6.  PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.

Authors:  Simona Camero; Simona Ceccarelli; Francesca De Felice; Francesco Marampon; Olga Mannarino; Lucrezia Camicia; Enrica Vescarelli; Paola Pontecorvi; Barry Pizer; Rajeev Shukla; Amalia Schiavetti; Maria Giovanna Mollace; Antonio Pizzuti; Vincenzo Tombolini; Cinzia Marchese; Francesca Megiorni; Carlo Dominici
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

Review 7.  Pregnancy after breast cancer in BRCA1/2 mutation carriers.

Authors:  Jelena Maksimenko; Arvīds Irmejs; Jānis Gardovskis
Journal:  Hered Cancer Clin Pract       Date:  2022-01-21       Impact factor: 2.857
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.